<DOC>
	<DOCNO>NCT00427557</DOCNO>
	<brief_summary>The goal clinical research study learn give umbilical cord blood along standard stem cell high-dose chemotherapy improve response stem cell transplant . The safety treatment also study .</brief_summary>
	<brief_title>Cellular Therapy With Cord Blood Cells</brief_title>
	<detailed_description>Cord blood source blood-forming cell use transplantation . Cord blood cell take umbilical cord woman give birth , volunteered donate umbilical cord . Researchers hope use cord blood stem cell transplant help reduce risk graft-versus-host-disease ( GVHD ) . GVHD occur donor cell attack cell person receive transplant . If find eligible take part study , receive chemotherapy 5 day . You receive fludarabine 30 minute needle vein Days 1-4 . You receive melphalan needle vein 30 minute Day 5 . On Day 7 , receive cord blood cell needle vein 30 minute . On Day 12 , receive blood stem cell needle vein 30-60 minute . The stem cell receive stem cell donor whose human leukocyte antigen ( HLA- protein cell ) type match . If appropriate disease , also receive rituximab weekly 4 week , begin day receive melphalan . Rituximab give though needle vein 2-3 hour . You receive drug tacrolimus methotrexate low risk GVHD . Tacrolimus give needle vein non-stop 2 week , start 12 hour stem cell transplant . After first 2 week , continue receive tacrolimus mouth , least 3 month . You receive methotrexate though needle vein 30 minute , start 1 day stem cell transplant , total 3 dos first 6 day stem cell transplant . You receive G-CSF ( granulocyte-colony stimulating factor ) help blood cell count recover . G-CSF give injection skin , begin 1 week stem cell transplant . You continue receive G-CSF day blood cell count reach certain high enough level . You need stay hospital 4 week begin Day 1 . While hospital , blood ( 2 teaspoon ) draw every day routine test . After leave hospital , return hospital visit 2-3 time week least 100 day transplant . During visit , physical exam blood ( 2 teaspoon ) draw routine test . You ask come back clinic follow-up visit 3 , 6 , 9 12 month transplant routine safety test . This include physical exam , bone marrow biopsy , blood ( 2 teaspoon ) draw routine testing . You consider off-study 12-month follow-up visit . This investigational study . The stem cell transplant , umbilical cord transplant , drug use study FDA approve . The use umbilical cord blood stem cell together investigational . Up 30 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients multiple myeloma ( MM ) , acute myeloid leukemia ( AML ) , myelodysplastic syndrome ( MDS ) , acute lymphoblastic leukemia ( ALL ) , nonHodgkin 's lymphoma ( NHL ) , Hodgkin 's lymphoma ( HL ) , chronic lymphocytic leukemia ( CLL ) great first complete remission candidate nonablative reduce intensity condition regimen . 2 . Age 80 year . 3 . A related unrelated donor HLAmatched HLA , A , B , C , DR DQ locus acceptable ( i.e . 10/10 match relate unrelated donor , match molecular highresolution technique per current standard BMT program ) . Donor must willing donate peripheral blood bone marrow progenitor cell . 4 . Available cord blood unit must contain minimum 1.5 * 10^7 total nucleated cell per kg , least 4/6 HLA match patient . 5 . Zubrod PS less equal 2 Lansky PS great equal 50 % . 6 . Left ventricular ejection fraction &gt; 40 % . No uncontrolled arrhythmias symptomatic heart disease . 7 . Forced Expiratory Volume 1 second ( FEV1 ) , Forced Vital Capacity ( FVC ) Diffusion Capacity ( DLCO ) &gt; 40 % . 8 . Serum creatinine &lt; 2.0 mg/dL . Serum bilirubin &lt; 3 * upper limit normal , SGPT &lt; 4 * upper limit normal . 1 . Patients active CNS disease 2 . Positive Beta HCG woman child bear potential define postmenopausal 12 month previous surgical sterilization . 3 . Serious medical psychiatric illness likely interfere participation clinical study , include limited active uncontrolled infection , uncontrolled cardiac arrhythmia ischemic event , uncontrolled psychosis , major depression , mania . 4 . Evidence chronic , active hepatitis cirrhosis , HIV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Cellular Therapy</keyword>
	<keyword>Umbilical Cord Blood Cells</keyword>
	<keyword>Cord Blood Transplantation</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>GVD</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
</DOC>